APO Research
Talk to an analyst

APO RESEARCH · REPORT

Capecitabine

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.

Selected research

Market Outlook & Growth Opportunities

Global Capecitabine Market Outlook and Growth Opportunities 2026

21 December 2025193 pages

Choose your research edition.

Industry ResearchCapecitabine Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Capecitabine Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Capecitabine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Capecitabine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Capecitabine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.

Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.

Read the full market overview

This report provides an overview of the global Capecitabine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Capecitabine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Capecitabine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Capecitabine market size, projected growth trends, production technologies, key applications, and end-use industries.

Capecitabine Segment by Company

Roche

Teva

Mylan

Hikma

Hengrui Medicine

Cipla

Reliance Group

Hetero

Capecitabine Segment by Type

500 mg

150 mg

Capecitabine Segment by Application

Breast Cancer

Colorectal Cancer

Stomach Cancer

Capecitabine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Capecitabine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Capecitabine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Capecitabine significant trends, drivers, influence factors in global and regions.

6. To analyze Capecitabine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Capecitabine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Capecitabine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Capecitabine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Capecitabine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Capecitabine industry.

Chapter 3: Detailed analysis of Capecitabine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Capecitabine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Capecitabine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Capecitabine Industry Trends Table 2. Capecitabine Industry Drivers Table 3. Capecitabine Industry Opportunities and Challenges Table 4. Capecitabine Industry Restraints Table 5. Global Capecitabine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Capecitabine Revenue Share by Company (2021-2026) Table 7. Global Capecitabine Sales Volume by Company (Kg) & (2021-2026) Table 8. Global Capecitabine Sales Volume Share by Company (2021-2026) Table 9. Global Capecitabine Average Price (USD/g) of Company (2021-2026) Table 10. Global Capecitabine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Capecitabine Key Company Manufacturing Base & Headquarters Table 12. Global Capecitabine Company, Product Type & Application Table 13. Global Capecitabine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Capecitabine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 500 mg Table 18. Significant Companies of 150 mg Table 19. Global Capecitabine Sales Volume by Type 2021 VS 2025 VS 2032 (Kg) Table 20. Global Capecitabine Sales Volume by Type (2021-2026) & (Kg) Table 21. Global Capecitabine Sales Volume by Type (2027-2032) & (Kg) Table 22. Global Capecitabine Sales Volume Share by Type (2021-2026) Table 23. Global Capecitabine Sales Volume Share by Type (2027-2032) Table 24. Global Capecitabine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Capecitabine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Capecitabine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Capecitabine Sales Value Share by Type (2021-2026) Table 28. Global Capecitabine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Breast Cancer Table 30. Significant Companies of Colorectal Cancer Table 31. Significant Companies of Stomach Cancer Table 32. Global Capecitabine Sales Volume by Application 2021 VS 2025 VS 2032 (Kg) Table 33. Global Capecitabine Sales Volume by Application (2021-2026) & (Kg) Table 34. Global Capecitabine Sales Volume by Application (2027-2032) & (Kg) Table 35. Global Capecitabine Sales Volume Share by Application (2021-2026) Table 36. Global Capecitabine Sales Volume Share by Application (2027-2032) Table 37. Global Capecitabine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Capecitabine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Capecitabine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Capecitabine Sales Value Share by Application (2021-2026) Table 41. Global Capecitabine Sales Value Share by Application (2027-2032) Table 42. Global Capecitabine Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 43. Global Capecitabine Sales by Region (2021-2026) & (Kg) Table 44. Global Capecitabine Sales Market Share by Region (2021-2026) Table 45. Global Capecitabine Sales by Region (2027-2032) & (Kg) Table 46. Global Capecitabine Sales Market Share by Region (2027-2032) Table 47. Global Capecitabine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Capecitabine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Capecitabine Sales Value Share by Region (2021-2026) Table 50. Global Capecitabine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Capecitabine Sales Value Share by Region (2027-2032) Table 52. Global Capecitabine Market Average Price (USD/g) by Region (2021-2026) Table 53. Global Capecitabine Market Average Price (USD/g) by Region (2027-2032) Table 54. Global Capecitabine Sales by Country: 2021 VS 2025 VS 2032 (Kg) Table 55. Global Capecitabine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Capecitabine Sales by Country (2021-2026) & (Kg) Table 57. Global Capecitabine Sales Market Share by Country (2021-2026) Table 58. Global Capecitabine Sales by Country (2027-2032) & (Kg) Table 59. Global Capecitabine Sales Market Share by Country (2027-2032) Table 60. Global Capecitabine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Capecitabine Sales Value Market Share by Country (2021-2026) Table 62. Global Capecitabine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Capecitabine Sales Value Market Share by Country (2027-2032) Table 64. Roche Company Information Table 65. Roche Business Overview Table 66. Roche Capecitabine Sales (Kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 67. Roche Capecitabine Product Portfolio Table 68. Roche Recent Development Table 69. Teva Company Information Table 70. Teva Business Overview Table 71. Teva Capecitabine Sales (Kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 72. Teva Capecitabine Product Portfolio Table 73. Teva Recent Development Table 74. Mylan Company Information Table 75. Mylan Business Overview Table 76. Mylan Capecitabine Sales (Kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 77. Mylan Capecitabine Product Portfolio Table 78. Mylan Recent Development Table 79. Hikma Company Information Table 80. Hikma Business Overview Table 81. Hikma Capecitabine Sales (Kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 82. Hikma Capecitabine Product Portfolio Table 83. Hikma Recent Development Table 84. Hengrui Medicine Company Information Table 85. Hengrui Medicine Business Overview Table 86. Hengrui Medicine Capecitabine Sales (Kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 87. Hengrui Medicine Capecitabine Product Portfolio Table 88. Hengrui Medicine Recent Development Table 89. Cipla Company Information Table 90. Cipla Business Overview Table 91. Cipla Capecitabine Sales (Kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 92. Cipla Capecitabine Product Portfolio Table 93. Cipla Recent Development Table 94. Reliance Group Company Information Table 95. Reliance Group Business Overview Table 96. Reliance Group Capecitabine Sales (Kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 97. Reliance Group Capecitabine Product Portfolio Table 98. Reliance Group Recent Development Table 99. Hetero Company Information Table 100. Hetero Business Overview Table 101. Hetero Capecitabine Sales (Kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 102. Hetero Capecitabine Product Portfolio Table 103. Hetero Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Capecitabine Distributors List Table 107. Capecitabine Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Capecitabine Product Image Figure 2. Global Capecitabine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Capecitabine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Capecitabine Sales (2021-2032) & (Kg) Figure 5. Global Capecitabine Sales Average Price (USD/g) & (2021-2032) Figure 6. Global Capecitabine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 500 mg Image Figure 10. 150 mg Image Figure 11. Global Capecitabine Sales Volume by Type (2021 VS 2025 VS 2032) & (Kg) Figure 12. Global Capecitabine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Capecitabine Sales Volume Share by Type (2021-2032) Figure 14. Global Capecitabine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Capecitabine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Capecitabine Sales Value Share by Type (2021-2032) Figure 17. Breast Cancer Image Figure 18. Colorectal Cancer Image Figure 19. Stomach Cancer Image Figure 20. Global Capecitabine Sales Volume by Application (2021 VS 2025 VS 2032) & (Kg) Figure 21. Global Capecitabine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Capecitabine Sales Volume Share by Application (2021-2032) Figure 23. Global Capecitabine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Capecitabine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Capecitabine Sales Value Share by Application (2021-2032) Figure 26. Global Capecitabine Sales by Region: 2021 VS 2025 VS 2032 (Kg) Figure 27. Global Capecitabine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Capecitabine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Capecitabine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Capecitabine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Capecitabine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Capecitabine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Capecitabine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Capecitabine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Capecitabine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Capecitabine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Capecitabine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Capecitabine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Capecitabine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Capecitabine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Capecitabine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Capecitabine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Capecitabine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Capecitabine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 500 mg
  • 150 mg
Applications
  • Breast Cancer
  • Colorectal Cancer
  • Stomach Cancer
Companies covered
  • Roche
  • Teva
  • Mylan
  • Hikma
  • Hengrui Medicine
  • Cipla
  • Reliance Group
  • Hetero

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Capecitabine Sales Value (2021-2032)
  4. 1.2.2 Global Capecitabine Sales Volume (2021-2032)
  5. 1.2.3 Global Capecitabine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Capecitabine Market Dynamics
  1. 2.1 Capecitabine Industry Trends
  2. 2.2 Capecitabine Industry Drivers
  3. 2.3 Capecitabine Industry Opportunities and Challenges
  4. 2.4 Capecitabine Industry Restraints
3 Capecitabine Market by Company
  1. 3.1 Global Capecitabine Company Revenue Ranking in 2025
  2. 3.2 Global Capecitabine Revenue by Company (2021-2026)
  3. 3.3 Global Capecitabine Sales Volume by Company (2021-2026)
  4. 3.4 Global Capecitabine Average Price by Company (2021-2026)
  5. 3.5 Global Capecitabine Company Ranking (2024-2026)
  6. 3.6 Global Capecitabine Company Manufacturing Base and Headquarters
  7. 3.7 Global Capecitabine Company Product Type and Application
  8. 3.8 Global Capecitabine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Capecitabine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Capecitabine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Capecitabine Market by Type
  1. 4.1 Capecitabine Type Introduction
  2. 4.1.1 500 mg
  3. 4.1.2 150 mg
  4. 4.2 Global Capecitabine Sales Volume by Type
  5. 4.2.1 Global Capecitabine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Capecitabine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Capecitabine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Capecitabine Sales Value by Type
  9. 4.3.1 Global Capecitabine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Capecitabine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Capecitabine Sales Value Share by Type (2021-2032)
5 Capecitabine Market by Application
  1. 5.1 Capecitabine Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Colorectal Cancer
  4. 5.1.3 Stomach Cancer
  5. 5.2 Global Capecitabine Sales Volume by Application
  6. 5.2.1 Global Capecitabine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Capecitabine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Capecitabine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Capecitabine Sales Value by Application
  10. 5.3.1 Global Capecitabine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Capecitabine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Capecitabine Sales Value Share by Application (2021-2032)
6 Capecitabine Regional Sales and Value Analysis
  1. 6.1 Global Capecitabine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Capecitabine Sales by Region (2021-2032)
  3. 6.2.1 Global Capecitabine Sales by Region: 2021-2026
  4. 6.2.2 Global Capecitabine Sales by Region (2027-2032)
  5. 6.3 Global Capecitabine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Capecitabine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Capecitabine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Capecitabine Sales Value by Region (2027-2032)
  9. 6.5 Global Capecitabine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Capecitabine Sales Value (2021-2032)
  12. 6.6.2 North America Capecitabine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Capecitabine Sales Value (2021-2032)
  15. 6.7.2 Europe Capecitabine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Capecitabine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Capecitabine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Capecitabine Sales Value (2021-2032)
  21. 6.9.2 South America Capecitabine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Capecitabine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Capecitabine Sales Value Share by Country, 2025 VS 2032
7 Capecitabine Country-level Sales and Value Analysis
  1. 7.1 Global Capecitabine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Capecitabine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Capecitabine Sales by Country (2021-2032)
  4. 7.3.1 Global Capecitabine Sales by Country (2021-2026)
  5. 7.3.2 Global Capecitabine Sales by Country (2027-2032)
  6. 7.4 Global Capecitabine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Capecitabine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Capecitabine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Capecitabine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Capecitabine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Capecitabine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Capecitabine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Capecitabine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Capecitabine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Capecitabine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Capecitabine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Capecitabine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Capecitabine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Capecitabine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Capecitabine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Capecitabine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Capecitabine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Capecitabine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Capecitabine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Capecitabine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Capecitabine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Capecitabine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Capecitabine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Capecitabine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Capecitabine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Capecitabine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Capecitabine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Capecitabine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Capecitabine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Capecitabine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Capecitabine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Capecitabine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Capecitabine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Capecitabine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Capecitabine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Capecitabine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Capecitabine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Capecitabine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Capecitabine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Capecitabine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Capecitabine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Capecitabine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Capecitabine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Capecitabine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Capecitabine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Capecitabine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Capecitabine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Capecitabine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Capecitabine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Capecitabine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Capecitabine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Capecitabine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Capecitabine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Capecitabine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Capecitabine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Capecitabine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Capecitabine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Capecitabine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Capecitabine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Capecitabine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Capecitabine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Capecitabine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Capecitabine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Capecitabine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Capecitabine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Capecitabine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Capecitabine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Capecitabine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Capecitabine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Capecitabine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Capecitabine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Capecitabine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Capecitabine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Capecitabine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Capecitabine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Capecitabine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Capecitabine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Capecitabine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Capecitabine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Capecitabine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Capecitabine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Capecitabine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Capecitabine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Capecitabine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Capecitabine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Capecitabine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Capecitabine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche Capecitabine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Roche Capecitabine Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Capecitabine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Capecitabine Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Capecitabine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Capecitabine Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Hikma
  20. 8.4.1 Hikma Company Information
  21. 8.4.2 Hikma Business Overview
  22. 8.4.3 Hikma Capecitabine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hikma Capecitabine Product Portfolio
  24. 8.4.5 Hikma Recent Developments
  25. 8.5 Hengrui Medicine
  26. 8.5.1 Hengrui Medicine Company Information
  27. 8.5.2 Hengrui Medicine Business Overview
  28. 8.5.3 Hengrui Medicine Capecitabine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hengrui Medicine Capecitabine Product Portfolio
  30. 8.5.5 Hengrui Medicine Recent Developments
  31. 8.6 Cipla
  32. 8.6.1 Cipla Company Information
  33. 8.6.2 Cipla Business Overview
  34. 8.6.3 Cipla Capecitabine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Cipla Capecitabine Product Portfolio
  36. 8.6.5 Cipla Recent Developments
  37. 8.7 Reliance Group
  38. 8.7.1 Reliance Group Company Information
  39. 8.7.2 Reliance Group Business Overview
  40. 8.7.3 Reliance Group Capecitabine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Reliance Group Capecitabine Product Portfolio
  42. 8.7.5 Reliance Group Recent Developments
  43. 8.8 Hetero
  44. 8.8.1 Hetero Company Information
  45. 8.8.2 Hetero Business Overview
  46. 8.8.3 Hetero Capecitabine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hetero Capecitabine Product Portfolio
  48. 8.8.5 Hetero Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Capecitabine Value Chain Analysis
  2. 9.1.1 Capecitabine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Capecitabine Sales Mode & Process
  6. 9.2 Capecitabine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Capecitabine Distributors
  9. 9.2.3 Capecitabine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst